|
Correlation Between The Expression Of Egfr And Pd-L1 With Prognosis Of Glioblastoma Multiforme Without Idh Mutation Treated With Nimotuzumab
|
|
| Author:
|
PATRICIA DIANA, LISYANI, SUROMO, UDADI SADHANA, HARDHONO SUSANTO, INDRA WIJAYA, CAHYONO KAELAN
|
| Abstract:
|
Glioblastoma Multiforme (GBM) without IDH mutation has lower overall survival rate, despite having been treated by the standard treatment regimen. Nimotuzumab was expected to improve survival. Expression of EGFR and PD-L1 protein can be used as biomarkers to evaluate the prognosis in patients treated with nimotuzumab. This study aimed to demonstrate the correlation between EGFR and PD-L1 expression with the prognosis (survival rate) of GBM without IDH mutation treated with nimotuzumab. The method of this study are cross-sectional analytic observational study. Total of 26 patients newly diagnosed with GBM without IDH mutation, where 13 were treated with nimotuzumab and 13 were treated without nimotuzumab. EGFR and PDL-1 expression were evaluated using immunohistochemistry. The results is patients treated with nimotuzumab showed significantly higher mean overall survival in comparison with those without treatment (12.23 ? 10.25 vs 6.31 ? 3.33 months, p<0.05). Patients treated with nimotuzumab also showed significantly higher 1- and 2-year survival rate (30.8% vs 15.4% and 7.7% vs 0%, p<0,05). Mean overall survival in the nimotuzumab treatment group was higher in patients with negative in comparison with positive EGFR expression (26.50 ? 24.75 vs 9.64 ? 4.08 months, p>0.05), with negative in comparison with moderate PD-L1 expression (13.80 ? 17.02 vs 11.25 ? 3.41 months, p>0.05). EGFR and PD-L1 expression has not been proven useful as prognostic markers.
|
| Keyword:
|
Glioblastoma multiforme, Nimotuzumab, prognosis, EGFR, PD-L1
|
| EOI:
|
-
|
| DOI:
|
https://doi.org/10.31838/ijpr/2020.12.01.270
|
| Download:
|
Request For Article
|
|
|